ICONOVO SIGNS AGREEMENT FOR DEVELOPMENT OF VACCINE AGAINST TUBERCULOSIS
Iconovo signs an agreement with McMaster University for development of vaccine against tuberculosis
The innovative Swedish medical technology company Iconovo AB announced today that the company has signed a partnership agreement with McMaster University in Canada. The agreement relates to the development of a dry powder preparation of inhalable vaccine against tuberculosis to be used in Iconovo’s unique single-dose inhaler ICOone.
Iconovo will be part of a multidisciplinary research and development project aimed at developing next-generation virus-based powder vaccine that is stable at room temperature. Being able to transport vaccines without the need for cold storage is a prerequisite for quickly and efficiently reaching out to the people who need it the most. In the current project, Iconovo’s unique disposable ICOone inhaler will be used as a test platform to facilitate future commercialization and large-scale manufacturing. The project is planned to last for three years and is partly financed by the Canadian state (CIHR / NSERC). Read more.